Rallybio Corporation announced that results from the RLYB212 Phase 1b proof-of-concept study will be presented at the 31stCongress of the International Society on Thrombosis and Haemostasis (ISTH), which will take place in Montreal from June 24-28. RLYB212 is an anti-HPA-1a monoclonal antibody being developed for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.48 USD | -0.67% | -11.38% | -38.08% |
15/05 | JPMorgan Downgrades Rallybio to Neutral From Overweight | MT |
09/05 | Rallybio Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.08% | 61.34M | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- RLYB Stock
- News Rallybio Corporation
- Rallybio to Present Data from the RLYB212 Phase 1b Proof-Of-Concept Study